



Company Announcement

27 April 2009

Novo Nordisk A/S – Share repurchase programme

On 29 January 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009.

Since the announcement as of 20 April 2009, the following transactions have been made under the programme:

| | Number of shares | Average purchase price | Transaction value, DKK |
|--|------------------|------------------------|------------------------|
| Accumulated, last announcement | 4,405,141 | | 1,222,317,085 |
| 20 April 2009 | 50,000 | 259.19 | 12,959,500 |
| 21 April 2009 | 77,500 | 260.82 | 20,213,550 |
| 22 April 2009 | 90,000 | 264.81 | 23,832,900 |
| 23 April 2009 | 90,000 | 267.30 | 24,057,000 |
| 24 April 2009 | 105,000 | 272.36 | 28,597,800 |
| Accumulated under the programme | 4,817,641 | | 1,331,977,835 |

With the transactions stated above, Novo Nordisk owns a total of 29,670,023 treasury shares, corresponding to 4.7% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.

The Annual General Meeting of Novo Nordisk A/S, which was held on 18 March 2009, approved a 2.2% reduction in the total share capital by cancellation of 14,000,000 treasury B shares of DKK 1 at a nominal value of DKK 14,000,000. After the legal implementation of the share capital reduction, which is expected to take place after expiry of the legal notice period in June 2009, Novo Nordisk's share capital will amount to DKK 620,000,000 divided into an A share capital of DKK 107,487,200 and a B share capital of DKK 512,512,800. Taking into account the expected cancellation Novo Nordisk would currently own 2.5% of such reduced share capital.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Media:

Outside North America:
Elin K Hansen
Tel: (+45) 4442 3450
ekh@novonordisk.com

In North America:
Sean Clements
Tel: (+1) 609 514 8316
secl@novonordisk.com

Investors:

Outside North America:
Mads Veggerby Lausten
Tel: (+45) 4443 7919
mlau@novonordisk.com

Kasper Roseeuw Poulsen
Tel: 4442 4471
krop@novonordisk.com

In North America:
Hans Rommer
Tel: (+1) 609 919 7937
hrrmm@novonordisk.com